Ostrowski Erik 4

What Happened

• Erik Ostrowski, SVP, Chief Financial Officer, Chief Business Officer & Treasurer of Akebia Therapeutics, was granted two awards on January 30, 2026: 204,000 restricted stock units (RSUs) and 320,000 stock options. Both grants are reported as acquisitions at $0.00 (no cash paid at grant).
• The RSUs and options were awarded under Akebia’s 2023 Stock Incentive Plan. The filing reports these as awards (transaction code A), not purchases or sales.

Key Details

• Transaction date: 2026-01-30; filing date (Form 4): 2026-02-03 (filed within the standard two-business-day window).
• Grant amounts and reported price: 204,000 RSUs @ $0.00; 320,000 options (derivative grant) @ $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • RSU vesting (F1): 1/3 vests on each of the first, second and third anniversaries of the grant, subject to continued service.
  • Option vesting (F2): Options vest over four years — 25% after one year, then the remaining 75% in equal quarterly installments, subject to continued service.
• No indication of exercise or sale of shares; these are grants (not exercises or transfers).

Context

• These grants are compensation awards and do not reflect an immediate cash purchase or sale; they become valuable only as they vest and, for options, if the strike price (not listed in this filing excerpt) is favorable relative to market price at exercise.
• For retail investors, awards are routine executive compensation and should be interpreted as part of pay structure rather than a direct bullish or bearish trade by the insider.